Short answer
Xencor Inc (XNCR) filed its fiscal 2025 10-K annual report with the SEC on Feb 25, 2026. It reported revenue of $126M (+13.7% year over year) and net income of −$92M.
- Top risk flagged: Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
FY2025 key financial metrics · XBRL
- Revenue
- $126M
- +13.7% YoY
- Net income
- −$92M
- +60.5% YoY
- Operating margin
- -141.4%
- +20.1 pp YoY
- EPS (diluted)
- −$1.24
- +65.4% YoY
- ROE
- -14.5%
- +19.9 pp YoY
- Operating cash flow
- −$135M
- +33.2% YoY
Source: XBRL data from the Xencor Inc (XNCR) FY2025 10-K on SEC EDGAR. USD.
Xencor Inc FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biopharma developing engineered XmAb antibody therapeutics targeting cancer and autoimmune diseases with modular bispecific Fc domain technology
- New product emphasis: XmAb412, a bispecific antibody targeting TL1A and IL23p19 in autoimmune diseases, first-in-human studies planned for 2026
- Strategic shift: Prioritization of T cell-engaging bispecific antibody programs in oncology, expanding XmAb 2+1 bispecific format applications in solid tumors
- Quantitative metric: Phase 1 XmAb819 RCC study enrolled 69 patients, 25% partial response rate, 70% disease control rate; XmAb942 Phase 2b initiated in ulcerative colitis
- Noteworthy fact: Collaboration revenues include $70.1M royalties from Alexion’s Ultomiris and $10.2M from Incyte’s Monjuvi in 2025, highlighting growing partner-generated income
Management Discussion & Analysis
- Revenue $125.6M in 2025, up $15.1M YoY from $110.5M in 2024, driven by Alexion and Incyte license agreements
- Operating loss $177.5M in 2025, nearly flat vs $178.4M in 2024, representing an operating margin of -141.3% vs -161.4%
- Best segment Royalties $80.3M in 2025, up $12.8M YoY; worst segment License revenues $0 in 2025 vs $8.5M in 2024
- Management emphasizes disciplined portfolio management and clinical data-driven strategy; no explicit forward guidance stated
Risk Factors
- Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
- Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity
- Supply chain vulnerability relying on third-party manufacturers, contract research organizations, and collaborators for manufacturing and clinical execution
- Competitive risk from other biotech/pharma firms with new products and technologies impacting market position and stock volatility
- Financial risk of significant net loss $91.9M in 2025, accumulated deficit $796.0M, requiring additional financing beyond $610.8M cash reserves to fund operations through 2028
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.